PROCEPT BioRobotics Corp·4

Mar 9, 5:40 PM ET

Waters Kevin 4

4 · PROCEPT BioRobotics Corp · Filed Mar 9, 2026

Research Summary

AI-generated summary of this filing

Updated

PROCEPT (PRCT) EVP/CFO Kevin Waters Sells Shares

What Happened Kevin Waters, EVP and Chief Financial Officer of PROCEPT BioRobotics (PRCT), had multiple transactions reported for March 2026. He received awards on March 5: 47,462 restricted stock units (RSUs) and a derivative award covering 32,576 shares (both reported at $0.00 acquisition price). On March 6 he sold 6,721 shares in an open‑market transaction at $23.70 per share, generating proceeds of $159,300. The sale was disclosed as to cover tax withholding obligations.

Key Details

  • Transaction dates and amounts:
    • 2026-03-05: Award of 47,462 RSUs (acquired at $0.00) — see footnote F1 for vesting.
    • 2026-03-05: Derivative award of 32,576 shares (acquired at $0.00) — see footnote F3 for vesting schedule.
    • 2026-03-06: Open‑market sale of 6,721 shares at $23.70 each = $159,300 (footnote F2: sale to cover tax withholding).
  • Shares owned after the transactions: not specified in the provided filing excerpt.
  • Footnotes:
    • F1: RSUs — 1/4 vest March 5, 2027; then 1/16 of the remaining RSUs vest quarterly over 36 months, subject to continued service.
    • F2: Sale was to satisfy tax withholding on vesting of Restricted Stock Units and Performance Stock Units.
    • F3: Derivative award vests 1/48th monthly starting March 5, 2026, over four years, subject to continued service.
  • Filing timeliness: Form 4 filed 2026-03-09 for transactions dated March 5–6 — reported within the usual two business‑day deadline (timely).

Context The sale was disclosed as a tax‑withholding sale tied to equity vesting (routine), while the March 5 entries represent equity awards (RSUs and an option-like derivative) that vest over time. Awards (acquisitions) are not immediate purchases of stock but contingent rights that convert to shares if vesting conditions are met.

Insider Transaction Report

Form 4
Period: 2026-03-05
Waters Kevin
EVP, CFO
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-05+47,462158,985 total
  • Sale

    Common Stock

    [F2]
    2026-03-06$23.70/sh6,721$159,300152,264 total
  • Award

    Stock Option (Right to Buy)

    [F3]
    2026-03-05+32,57632,576 total
    Exercise: $25.35Exp: 2036-03-04Common Stock (32,576 underlying)
Footnotes (3)
  • [F1]These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on March 5, 2027, with onesixteenth of the remaining RSUs vesting quarterly over 36 months, subject to the Reporting Person continuing as a service provider through such date.
  • [F2]These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units and Performance Stock Units.
  • [F3]1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2026, over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date.
Signature
/s/ Jonathan Stone, Attorney-in-Fact for Kevin Waters|2026-03-09

Documents

1 file
  • 4
    wk-form4_1773092446.xmlPrimary

    FORM 4